Cargando…
PSAT225 Severe Hypercalcemia Following Denosumab Withdrawal in Giant Cell Tumor of Bone: A Double-edged Sword Treatment Paradigm?
INTRODUCTION: Denosumab inhibits receptor activator of nuclear factor k-B ligand and is approved to treat giant cell tumor of bone (GCTB). Rebound hypercalcemia is a rare complication of denosumab withdrawal in pediatrics which is not reported in adults. We describe severe hypercalcemia in an adult...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624746/ http://dx.doi.org/10.1210/jendso/bvac150.452 |